This study reveals FGFR4 as a key driver of lipid metabolism in CRC and demonstrates that isoliquiritigenin (ISL) effectively inhibits tumor progression by targeting the FGFR4/FASN pathway. The gene discussed is FASN; the disease is neoplasm.